Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A

Junichi Inokuchi, Kentaro Kuroiwa, Yoshiyuki Kakehi, Mikio Sugimoto, Toshiki Tanigawa, Hiroyuki Fujimoto, Momokazu Gotoh, Naoya Masumori, Osamu Ogawa, Masatoshi Eto, Chikara Ohyama, Akito Yamaguchi, Hideyasu Matsuyama, Tomohiko Ichikawa, Tomohiko Asano, Junki Mizusawa, Junko Eba, Seiji Naito

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To evaluate the impact of lymph node dissection (LND) on clinical outcome during radical nephroureterectomy (RNU) for patients with upper urinary tract urothelial cancer (UTUC). Methods: We, the Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG), retrospectively collected data from patients with non-metastatic UTUC who underwent RNU in 30 centers in 1995–2009. Ineligible patients and patients with previous and/or synchronous bladder cancer were excluded, and the remaining 2037 patients were analyzed. We compared overall and cancer-specific mortality between patients who underwent LND (LND group) and those without LND (no-LND group). Results: Among 2037 patients, LND was performed in 1046 (51.4%) patients, and 223 (10.9%) patients had pathological node-positive (pN+) disease. All-cause mortality was observed in 503 patients (24.7%) during follow-up (median 45.8 months), including 363 patients (17.8%) who died of UTUC. Patients with pN+ disease showed significantly shorter overall survival (OS) compared with pN0 patients, and the estimated 5-year OS for pN+ patients was 30%. Older age, ≥cT3, and clinical node-positive disease were found as preoperative predictors for pN+ disease by multivariate analysis. In the comparison of OS and cancer-specific mortality between LND and no-LND groups, there was no significant improvement by LND in multivariate analysis. The median number of lymph nodes removed was six (IQR 3–11). There was no significant association between the number of lymph nodes removed and OS. Conclusions: The present study indicates that there is no therapeutic benefit of LND during RNU for UTUC, although pathologically positive LN status can predict poor prognosis.

Original languageEnglish
Pages (from-to)1737-1744
Number of pages8
JournalWorld Journal of Urology
Volume35
Issue number11
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Urologic Neoplasms
Lymph Node Excision
Retrospective Studies
Survival
Mortality
Multivariate Analysis
Lymph Nodes
Medical Oncology

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer : multi-institutional large retrospective study JCOG1110A. / Inokuchi, Junichi; Kuroiwa, Kentaro; Kakehi, Yoshiyuki; Sugimoto, Mikio; Tanigawa, Toshiki; Fujimoto, Hiroyuki; Gotoh, Momokazu; Masumori, Naoya; Ogawa, Osamu; Eto, Masatoshi; Ohyama, Chikara; Yamaguchi, Akito; Matsuyama, Hideyasu; Ichikawa, Tomohiko; Asano, Tomohiko; Mizusawa, Junki; Eba, Junko; Naito, Seiji.

In: World Journal of Urology, Vol. 35, No. 11, 01.11.2017, p. 1737-1744.

Research output: Contribution to journalArticle

Inokuchi, J, Kuroiwa, K, Kakehi, Y, Sugimoto, M, Tanigawa, T, Fujimoto, H, Gotoh, M, Masumori, N, Ogawa, O, Eto, M, Ohyama, C, Yamaguchi, A, Matsuyama, H, Ichikawa, T, Asano, T, Mizusawa, J, Eba, J & Naito, S 2017, 'Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A', World Journal of Urology, vol. 35, no. 11, pp. 1737-1744. https://doi.org/10.1007/s00345-017-2049-x
Inokuchi, Junichi ; Kuroiwa, Kentaro ; Kakehi, Yoshiyuki ; Sugimoto, Mikio ; Tanigawa, Toshiki ; Fujimoto, Hiroyuki ; Gotoh, Momokazu ; Masumori, Naoya ; Ogawa, Osamu ; Eto, Masatoshi ; Ohyama, Chikara ; Yamaguchi, Akito ; Matsuyama, Hideyasu ; Ichikawa, Tomohiko ; Asano, Tomohiko ; Mizusawa, Junki ; Eba, Junko ; Naito, Seiji. / Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer : multi-institutional large retrospective study JCOG1110A. In: World Journal of Urology. 2017 ; Vol. 35, No. 11. pp. 1737-1744.
@article{4f0842d440ad41ce948ce47204b706f7,
title = "Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A",
abstract = "Purpose: To evaluate the impact of lymph node dissection (LND) on clinical outcome during radical nephroureterectomy (RNU) for patients with upper urinary tract urothelial cancer (UTUC). Methods: We, the Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG), retrospectively collected data from patients with non-metastatic UTUC who underwent RNU in 30 centers in 1995–2009. Ineligible patients and patients with previous and/or synchronous bladder cancer were excluded, and the remaining 2037 patients were analyzed. We compared overall and cancer-specific mortality between patients who underwent LND (LND group) and those without LND (no-LND group). Results: Among 2037 patients, LND was performed in 1046 (51.4{\%}) patients, and 223 (10.9{\%}) patients had pathological node-positive (pN+) disease. All-cause mortality was observed in 503 patients (24.7{\%}) during follow-up (median 45.8 months), including 363 patients (17.8{\%}) who died of UTUC. Patients with pN+ disease showed significantly shorter overall survival (OS) compared with pN0 patients, and the estimated 5-year OS for pN+ patients was 30{\%}. Older age, ≥cT3, and clinical node-positive disease were found as preoperative predictors for pN+ disease by multivariate analysis. In the comparison of OS and cancer-specific mortality between LND and no-LND groups, there was no significant improvement by LND in multivariate analysis. The median number of lymph nodes removed was six (IQR 3–11). There was no significant association between the number of lymph nodes removed and OS. Conclusions: The present study indicates that there is no therapeutic benefit of LND during RNU for UTUC, although pathologically positive LN status can predict poor prognosis.",
author = "Junichi Inokuchi and Kentaro Kuroiwa and Yoshiyuki Kakehi and Mikio Sugimoto and Toshiki Tanigawa and Hiroyuki Fujimoto and Momokazu Gotoh and Naoya Masumori and Osamu Ogawa and Masatoshi Eto and Chikara Ohyama and Akito Yamaguchi and Hideyasu Matsuyama and Tomohiko Ichikawa and Tomohiko Asano and Junki Mizusawa and Junko Eba and Seiji Naito",
year = "2017",
month = "11",
day = "1",
doi = "10.1007/s00345-017-2049-x",
language = "English",
volume = "35",
pages = "1737--1744",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer

T2 - multi-institutional large retrospective study JCOG1110A

AU - Inokuchi, Junichi

AU - Kuroiwa, Kentaro

AU - Kakehi, Yoshiyuki

AU - Sugimoto, Mikio

AU - Tanigawa, Toshiki

AU - Fujimoto, Hiroyuki

AU - Gotoh, Momokazu

AU - Masumori, Naoya

AU - Ogawa, Osamu

AU - Eto, Masatoshi

AU - Ohyama, Chikara

AU - Yamaguchi, Akito

AU - Matsuyama, Hideyasu

AU - Ichikawa, Tomohiko

AU - Asano, Tomohiko

AU - Mizusawa, Junki

AU - Eba, Junko

AU - Naito, Seiji

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose: To evaluate the impact of lymph node dissection (LND) on clinical outcome during radical nephroureterectomy (RNU) for patients with upper urinary tract urothelial cancer (UTUC). Methods: We, the Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG), retrospectively collected data from patients with non-metastatic UTUC who underwent RNU in 30 centers in 1995–2009. Ineligible patients and patients with previous and/or synchronous bladder cancer were excluded, and the remaining 2037 patients were analyzed. We compared overall and cancer-specific mortality between patients who underwent LND (LND group) and those without LND (no-LND group). Results: Among 2037 patients, LND was performed in 1046 (51.4%) patients, and 223 (10.9%) patients had pathological node-positive (pN+) disease. All-cause mortality was observed in 503 patients (24.7%) during follow-up (median 45.8 months), including 363 patients (17.8%) who died of UTUC. Patients with pN+ disease showed significantly shorter overall survival (OS) compared with pN0 patients, and the estimated 5-year OS for pN+ patients was 30%. Older age, ≥cT3, and clinical node-positive disease were found as preoperative predictors for pN+ disease by multivariate analysis. In the comparison of OS and cancer-specific mortality between LND and no-LND groups, there was no significant improvement by LND in multivariate analysis. The median number of lymph nodes removed was six (IQR 3–11). There was no significant association between the number of lymph nodes removed and OS. Conclusions: The present study indicates that there is no therapeutic benefit of LND during RNU for UTUC, although pathologically positive LN status can predict poor prognosis.

AB - Purpose: To evaluate the impact of lymph node dissection (LND) on clinical outcome during radical nephroureterectomy (RNU) for patients with upper urinary tract urothelial cancer (UTUC). Methods: We, the Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG), retrospectively collected data from patients with non-metastatic UTUC who underwent RNU in 30 centers in 1995–2009. Ineligible patients and patients with previous and/or synchronous bladder cancer were excluded, and the remaining 2037 patients were analyzed. We compared overall and cancer-specific mortality between patients who underwent LND (LND group) and those without LND (no-LND group). Results: Among 2037 patients, LND was performed in 1046 (51.4%) patients, and 223 (10.9%) patients had pathological node-positive (pN+) disease. All-cause mortality was observed in 503 patients (24.7%) during follow-up (median 45.8 months), including 363 patients (17.8%) who died of UTUC. Patients with pN+ disease showed significantly shorter overall survival (OS) compared with pN0 patients, and the estimated 5-year OS for pN+ patients was 30%. Older age, ≥cT3, and clinical node-positive disease were found as preoperative predictors for pN+ disease by multivariate analysis. In the comparison of OS and cancer-specific mortality between LND and no-LND groups, there was no significant improvement by LND in multivariate analysis. The median number of lymph nodes removed was six (IQR 3–11). There was no significant association between the number of lymph nodes removed and OS. Conclusions: The present study indicates that there is no therapeutic benefit of LND during RNU for UTUC, although pathologically positive LN status can predict poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85019233864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019233864&partnerID=8YFLogxK

U2 - 10.1007/s00345-017-2049-x

DO - 10.1007/s00345-017-2049-x

M3 - Article

C2 - 28508102

AN - SCOPUS:85019233864

VL - 35

SP - 1737

EP - 1744

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 11

ER -